Thursday, September 30, 2010

Ground Broken For NCI

Ground was broken recently for a National Cancer Institute facility in Montgomery County,Maryland.Part of a Johns Hopkins University campus,the 200 million dollar project will consist of 575,000 square feet of office space over two connected buildings.It will house 2100 workers at completion in 2013,and is sited next to three JHU buildings already on Medical Center Drive.The buildings will be seven stories high and include retail space and a parking garage as well.
The project is part of the Shady Grove Life Sciences Center in the D.C. suburb of Rockville,Maryland.It will cover nine acres on the JHU campus,which is home to 16 biotech firms and serves 4,000 students and 450 faculty annually.The NCI facility supplements two others it currently occupies in Montgomery County.
Johns Hopkins University was the leading academic institution for total R&D spending in fiscal 2009 for the 31st consecutive year,according to the National Science Foundation.JHU spent 1.85 billion on medical,science and engineering research.
Johns Hopkins is spearheading a science city project in Montgomery County,Maryland.

Sunday, September 26, 2010

The Key Investor Question

For a financial advisor,the key is what investors are seeking.Doug Cliggott,Chief Equity Strategist at Credit Suisse,says CS is looking at a society that's getting older.They think it makes sense that investors are seeking less risk.The kind of high yield,low beta equities investors need are names such as AT&T,Pfizer,PepsiCo and McDonald's.
We need to alter our structure of taxation.We need plant and equipment investing.Companies aren't investing because there's no growth.Who isn't frustrated?We're about the same place we were 12 months ago,but with extraordinary volatility.In that world,it makes sense that people are seeking the perceived security of the bond market.That's why CS recommends low volatility stocks with good yields.
A year from now,we could well be where we are right now.Earnings next year could be where we are this year.It's a dangerous,high risk environment,Doug Cliggott believes.
Credit Suisse(CS),AT&T(T),Pfizer(PFE),PepsiCo(PEP),McDonald's(MCD)

Xerox Expands Business Model

Xerox has been augmenting its business model recently.There is nothing growing faster than data,CEO Ursula Burns observes.Their approach is to make the data overflow more useful.Xerox is spending a lot on educating its sales force about this,and is funding the business by becoming more efficient.
Smaller devices and high end color had a step-out in Q2.The one place Xerox is gonna focus is outside the U.S.,taking business process outsourcing where it hasn't been introduced.They're also spending sales dollars on educating people that Xerox has solutions to cost-effective color printing.Most business processing is done internally,so there is a big market for outsourcing out there.Companies would like to spend more time on their real business of serving their customers.
At its core,Xerox is a huge technology company.When they get cash,their number one requirement is paying down their debt:the Affiliated Computer Services acquisition.That should be accomplished by mid-2011.Then Xerox will turn to shareholder return and investing.
Xerox is a different company today.They help companies manage their infrastructure effectively.Pay attention to what Xerox is today,helping its clients change their businesses and serve their customers better,CEO Ursula Burns pleads.
Xerox was recently upgraded in a Barron's magazine article for this move into outsourcing.

New York Life Still Hiring

New York Life has stood strong throughout the financial crisis,which is why it is still hiring today.Many successful individuals have already improved their prospects by joining this leading firm.Honored by Fortune magazine as one of the world's most admired companies,it has lead the U.S. in sales of life insurance and lifetime income annuities.
New York Life offers comprehensive professional training,the latest technological tools and substantial compensation opportunities.Please fill out the form at to be contacted by a recruiter.

Thursday, September 23, 2010

In Depth:Seasonal Flu Vaccine 2010-2011

The annual seasonal influenza vaccine is being rolled out nationwide,and the Centers for Disease Control has released guidelines for the vaccine.This year,the vaccine provides protection against the HIN1,H3N2 and influenza B strains.Flu season usually peaks around January,but outbreaks are possible as early as October.It takes about two weeks to develop the protective antibodies stimulated by the vaccine.
The injection form of the vaccine is approved for most people older than six months of age.The FluMist inhaled vaccine is for healthy people between 2-49 years of age who are not pregnant.
Those at high risk for flu include pregnant women;those who are 50+;those of any age with certain chronic illnesses;people in nursing homes or other long term care facilities;and those who care for any of the above groups.
Certain people should consult a physician before being vaccinated:those with a severe chicken egg allergy;those who have had a severe reaction to a previous flu vaccine;those who developed Guillan-Barre syndrome within six weeks of getting a flu vaccine;children less than six months old;and those with a moderate to severe illness with a fever,who should wait until they recover.
The vaccine offers protection only against specific strains of influenza.It provides about a 70% chance of being protected from those strains.

Sunday, September 19, 2010

Boeing Developing Space Capsule

Through its Space Exploration division,Boeing is developing a multiple use space capsule,the Boeing Crew Space Transportation-100.Boeing plans to use the CST-100 to transport crews to the International Space Station and future commercial Low Earth Orbit platforms.
The capsule can carry up to seven people.It can fly on multiple launch vehicles,and is expected to be operational by 2015.
In cooperation with Space Adventures,a Vienna,Virginia firm which has marketed spare seats on the Russian Soyuz spacecraft,Boeing plans to offer safe,affordable transportation to commercial spaceflight customers in the excess seating capacity of the CST-100.
These plans are contingent upon congrssional approval of funds for commercial space flight and Boeing's winning a NASA contract for astronaut transportation.Congress and the Obama administration are still wrangling over the future of NASA's manned spaceflight program.The space shuttle is to be retired next year.

Market Strategist Sees Grinding

Stephen Wood,Chief Market Strategist at Russell Investments,thinks we just kind of grind it up.It's gonna increasingly be a stock picker's market.Some of his current investment preferences are areas of consumer discretionary,staples,tech,commodities and fixed income.
Dr.Wood isn't convinced the upcoming U.S. election is all-important.He thinks we'll probably grind through more of the same.
Stephen Wood holds a PhD in International Political Economy from Claremont College.He helps manage more than 140 billion dollars of assets at Russell Investments,which serves more than 2900 institutional clients and millions of individual investors in 46 countries.
Russell Investments is the creator of the noted Russell Global Indexes,such as the Russell 2000 small cap index.It manages more than 400 investment funds.

Professional/General Positions

The Washington Post Mega Career Fair will include a Professional/General Pavilion for all experience levels.Exhibitors such as Allstate,Amtrak,Fairfax County Public Schools and the Transportation Security Administration will be present.Positions ranging from sales and management to marketing and HR will be recruited for.A hard copy of your resume must be submitted at the event.It will be held on Wednesday,September 22 from 11am-5pm at
Sheraton National Crystal City
900 South Orme Street
Arlington,VA 22204
For more information,visit

Thursday, September 16, 2010

Biotech's Respiratory Virus Treatment:FDA Dissatisfied

The Food and Drug Administration has requested that biotech firm MedImmune conduct further study of its respiratory virus treatment motavizumab.MedImmune recieved a complete response letter from the FDA asking for an additional clinical trial of motavizumab that supports a satisfactory risk/benefit profile.MedImmune,the biologics unit of British drugmaker AstraZeneca,said it will thoroughly review the letter and make a decision in due course about motavizumab,which it says it continues to believe in.It was the second complete response letter it had recieved from the FDA in the course of seeking approval for the treatment.
Motavizumab is being investigated to treat respiratory syncytial virus,which poses a threat to certain infants and adults.RSV typically causes a mild cold-like illness that clears up within a few weeks,but can be more severe,causing pneumonia or bronchitis in young babies,premature babies or adults,especially those with chronic heart or lung problems-possibly leading to death and requiring hospitalization.
Motavizumab is a monoclonal antibody,which is an antibody produced by a cloned cell that binds to a targeted cell,potentially stimulating the patient's immune system to attack the target cell.
Based in Gaithersburg,Maryland,MedImmune employs about 3300 people worldwide.It also has facilities in Frederick,Maryland and Cambridge,U.K.

Sunday, September 12, 2010

Bryn Mawr Trust:Seeing Signs,Adjusting The Portfolio

Bryn Mawr Trust believes that corporate America will continue to strengthen,then hire and bring consumers back in.The trust is starting to see signs this economy is improving.They've lowered their large cap stock weighting and raised their mid-cap and small cap weightings.
Emerging markets will continue to be a good place for long term investors,although you will see your ups and downs,according to Eric Thorne,Vice-President and Senior Portfolio Manager at Bryn Mawr Trust.
Bryn Mawr Trust is a full service bank for individuals,affluent families,closely-held businesses and non-profit organizations.It is based in Bryn Mawr,Pennsylvania,which is near Philadelphia.
Bryn Mawr Bank Corporation(BMTC)

Rental Apartments Reveal Facts

Richard LeFrak,head of The LeFrak Organization,a major developer,says he deals with consumers at an interesting level.In certain markets,there's an increased demand for rental apartments.It means the sale business has been tainted,but it also means people are able to deal with their necessities.
Mr.LeFrak thinks there's some recognition by the government that the flailing of the past 18 months didn't achieve what they wanted to achieve.This coming election is gonna have to do with people's attitude about the future:optimism or pessimism.Hiring follows optimism.We'll have to see what November brings.
The LeFrak Organization,which is privately held,was founded by Mr.LeFrak's grandfather,Harry,in 1901.Besides large scale residential and commercial real estate development and management in New York,Los Angeles and London,it holds onshore energy assets and a securities portfolio.

Community College Jobs

Northern Virginia Community College,a major institution in the D.C. suburbs,is currently hiring.The school enrolls over 75,000 on six campuses and its Extended Learning Institute.NOVA is Virginia's largest institution of higher learning and one of America's largest community colleges.
For more information and to complete the required online application,those interested should visit and click on the jobs link.

Thursday, September 9, 2010

Vitamin D and Colorectal Cancer

Those with higher vitamin D levels appear less likely to develop colorectal cancer in the first place;but if they do,they seem less likely to die from it,a recent study published in the Journal of Clinical Oncology found.The study set out to explore the influence of vitamin D on the outcome of patients with established colorectal cancer.It found that higher vitamin D levels were associated with a significant reduction in overall mortality,and a trend toward improved colorectal cancer mortality was also observed.
The study concluded that,among colorectal cancer patients,higher prediagnosis vitamin D levels were associated with a significant improvement in overall survival.Further study of the vitamin D pathway and its influence on colorectal cancer origins and progression is warranted,the authors felt.Corresponding author was Kimmie Ng,MD,MPH,of the Dana-Farber Cancer Institute in Boston.
Colorectal cancer is diagnosed in 112,000 Americans every year.Its incidence has also been associated with red meat and processed meat consumption.
The publisher is not responsible for readers' decisions regarding health,finance or any other matter.They should seek professional advice before making important decisions such as a change in diet or the purchase of securities.


Sunday, September 5, 2010

Analyst:Texas Instruments Looking Good

Texas Instruments is in a great position right now,according to Patrick Wang of Wedbush Morgan Securities.It has bought manufacturing capacity at a bargain level.It's interested in continuing a small acquisition strategy with its 2.3 billion in cash.
Mr.Wang doesn't see TXN levering up its balance sheet.They've added 4.5 billion in extra capacity in the last year.They bought it at pennies on the dollar.It's a buffer for the electronics firm against a double dip recession or slowing market trends,in Mr.Wang's opinion.
Texas Instruments(TXN)

TD Bank's Priority Works

Toronto Dominion Bank has seen its profit soar 29% recently.CEO Ed Clark said they really like the firm's business mix.They are 85% retail and 15% wholesale.Their trading revenues were down,but retail earnings were up.While wholesale income fell 45%,the U.S. division's revenue grew 17%.TD is the only bank that grows its loans every quarter,Mr.Clark asserts.
TD Bank is open about 50% more hours than anyone else.They generally like to keep the loans on their books.If they do sell them off,they like to have a servicing agreement so they can still serve their clients.The AAA-rated bank has reoriented its wholesale business to be conservative,not take risks,Ed Clark maintains.
Toronto Dominion Bank(TD)

Foxconn Cuts Growth Target

Taiwan's Foxconn Technology Group,the world's largest contract electronics maker,has slashed its long term growth target in half,from 30% to 15%,which may ease the pressure on its huge workforce of one million.The company was racked by a rash of employee suicides earlier this year,as well as the recent falloff in pc sales.It does work for Hewlett Packard,Dell and Apple,as well as Cisco and Nokia,making everything from handsets to servers.
Despite having a bigger market capitalization than Sony,Foxconn has been the worst performer on Hong Kong's Hang Seng index this year,with a profit decline of 44.46%.There are no buy ratings on the stock of the troubled firm.Terry Gou,59,is the forthright Taiwanese founder of the company,and says he has no intention of retiring anytime soon.

Thursday, September 2, 2010

Pfizer Acquires Biotech Firm

Pfizer,a world-leading drug producer and marketer,is to acquire FoldRx,a privately held company that specializes in innovative oral medicines to treat diseases caused by protein misfolding.Protein misfolding is increasingly considered an underlying cause of many chronic degenerative conditions.FoldRx's main candidate,tafamidis,is registered as an oral therapy for TTR amyloid polyneuropathy,or ATTR-PN,a progressively fatal genetic neurological disorder.The biotech firm has filed a marketing application for tafamidis with the European Medicines Agency,and the drug has been fast-tracked by the FDA.
To this point,only liver transplants have been available to treat ATTR-PN.Liver transplants are not uniformly effective and are often fatal in their own right.At least 8,000 patients worldwide have ATTR-PN,most of them in the European Union.
TTR is a liver protein that,when defective,gets lodged in peripheral nerve tissue,causing neurological disorders such as ATTR-PN.
FoldRx's small molecule therapeutics,based on proprietary expertise,are also being applied to a discovery program in cystic fibrosis,Parkinson's and Huntington's diseases.Pfizer sees the acquisition of FoldRx as a way to bolster its rare disease portfolio and assist the patients with its medical,administrative,manufacturing and marketing proficiencies.